WELCOME TO AIMM THERAPEUTICS
AIMM Therapeutics (AIMM) is a leading antibody company that uses its synergistic, state of the art antibody technology platforms to generate therapeutic human monoclonal antibodies for the areas of oncology and infectious diseases. AIMM develops high affinity monoclonal antibodies directly from immortalized, selected B-cells of cancer patients and individuals exposed to infectious agents, who produce antibodies with high therapeutic value. These naturally occurring antibodies have excellent physico-chemical properties. AIMM’s technology platforms are also fully validated for a variety of non-human species including immunized mice, rabbits, llamas and non‐human primates.
Utilizing its patented AIMSelectTM platform, AIMM is able to immortalize the full B-cell repertoire and to select the relevant antibody producing B-cell clones with unprecedented efficiency. AIMSelectTM is one thousand fold more efficient than current leading hybridoma technologies and covers a much broader B-cell repertoire.
If desired, AIMM’s antibodies can be further affinity matured in its proprietary AIMproveTM process that does not require molecular engineering.
AIMM has a broad product pipeline that includes novel antibodies targeting Acute Myeloid Leukemia and melanoma and infectious diseases caused by Influenza-, Cytomegalo-, Hepatitis B- and C- and Human Respiratory virus.
The first generation of AIMM’s antibodies against Respiratory Syncytial Virus, Influenza Virus and Methicillin Resistant Staphylococcus aureus (MRSA) are partnered and are currently in clinical trials or undergoing late stage preclinical testing. AIMM has partnerships with MedImmune/AstraZeneca, Genentech/Roche, Johnson& Johnson and Cosmo pharmaceuticals.